Edition:
United States

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

15.75USD
20 Jul 2018
Change (% chg)

$0.10 (+0.64%)
Prev Close
$15.65
Open
$15.70
Day's High
$15.90
Day's Low
$15.60
Volume
150,692
Avg. Vol
324,473
52-wk High
$24.45
52-wk Low
$8.15

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 0.39
Market Cap(Mil.): $974.59
Shares Outstanding(Mil.): 62.27
Dividend: --
Yield (%): --

Financials

  DVAX.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -1.87 -- --
ROI: -58.90 -3.65 13.18
ROE: -82.67 -5.62 15.09

BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 08 2018

BRIEF-Dynavax Technologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

May 07 2018

BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma

* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

Apr 17 2018

BRIEF-Dynavax Qtrly Loss Per Share $0.45

* DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing

* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING

Feb 20 2018

Competitors

Earnings vs. Estimates